Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Layla Lucas

Vascular Surgery Tucson, AZ Medical Doctor

NPI 1326210071 CMS profile 105816

6442 E Speedway Blvd Ste 102, Ste 102, Tucson, AZ 85710

Open in the dashboard

General payments

$15,506

530 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Layla Lucas of Tucson, AZ is reported in the CMS Open Payments database as having received $15,506 across 530 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 77th percentile of Vascular Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,062 38
2024 General $1,933 61
2023 General $3,395 102
2022 General $2,431 83
2021 General $2,500 103
2020 General $2,805 76
2019 General $1,381 67

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Layla Lucas
  • Vascular Surgery median
  • Middle half of Vascular Surgery
  • National median

In program year 2025, general payments to Layla Lucas were reported at $1,062. Among 3,991 Vascular Surgery profiles paid that year, the median was $924 and the middle half received between $273 and $2,636.

Show as a table
Year Layla Lucas Vascular Surgery median Middle half National median
2019 $1,381 $796 $226–$2,363 $163
2020 $2,805 $348 $118–$1,110 $114
2021 $2,500 $471 $158–$1,421 $132
2022 $2,431 $725 $222–$2,183 $149
2023 $3,395 $836 $257–$2,440 $160
2024 $1,933 $909 $252–$2,619 $164
2025 $1,062 $924 $273–$2,636 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Medtronic, Inc. $4,346 165 payments
  2. W. L. Gore & Associates, Inc. $1,490 38 payments
  3. Musculoskeletal Transplant Foundation Inc. $1,373 3 payments
  4. Medtronic Vascular, Inc. $1,328 86 payments
  5. Penumbra, Inc. $823 23 payments
  6. Endologix, Inc. $739 16 payments
  7. Smith+Nephew, Inc. $618 40 payments
  8. Bolton Medical Inc $608 5 payments
  9. Tactile Systems Technology Inc $445 27 payments
  10. Boston Scientific Corporation $434 14 payments
  11. Other $3,301 113 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $14,322 523 payments
  2. Travel and Lodging $1,184 7 payments
Products named General payments · program years 2019–2025
  1. TurboHawk $1,288 15 payments
  2. HawkOne Directional Atherectomy Devices $857 51 payments
  3. HawkOne Directional Atherectomy Devices $721 39 payments
  4. Indigo System $676 18 payments
  5. Alto Abdominal Stent Graft System $559 10 payments
  6. FLOWTRIEVER CATHETER, S $462 12 payments
  7. GORE VIABAHN VBX Balloon Expandable Endo $439 11 payments
  8. Valiant Captivia $425 7 payments
  9. ENROUTE Transcarotid Stent $344 6 payments
  10. ENROUTE Transcarotid Neuroprotection System $344 6 payments
  11. Other $11,405 476 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 2 drugs

Part D claims

96

Median for Vascular Surgery: 122

Drug cost

$63,303

Median for Vascular Surgery: $14,135

Branded share of claims

100%

Median for Vascular Surgery: 71%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Xarelto Rivaroxaban Brand 52 $62,749
Clopidogrel Clopidogrel Bisulfate Brand 44 $554

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,087 Part D prescribers listed as Vascular Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 69 billing codes

Paid by Medicare

$237,185

Medicare's payments for the services billed

Medicare patients

967

Average age 77

Services billed

2,015

537 women, 430 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 54%
Ischemic heart disease 45%
Chronic kidney disease 39%
Diabetes 38%
Atrial fibrillation 32%
Depression 28%
Heart failure 27%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

2 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
XARELTO
  • Janssen Pharmaceuticals, Inc $55
$55 52 —
Qutenza
  • Averitas Pharma Inc. $19
$19 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

530 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Vascular Surgery in Arizona

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record